Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

130 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events.
Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, Kastelein JJ, Bittner V, Fruchart JC; Treating to New Targets Investigators. Barter P, et al. Among authors: szarek m. N Engl J Med. 2007 Sep 27;357(13):1301-10. doi: 10.1056/NEJMoa064278. N Engl J Med. 2007. PMID: 17898099 Free article. Clinical Trial.
LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer.
Tavazoie MF, Pollack I, Tanqueco R, Ostendorf BN, Reis BS, Gonsalves FC, Kurth I, Andreu-Agullo C, Derbyshire ML, Posada J, Takeda S, Tafreshian KN, Rowinsky E, Szarek M, Waltzman RJ, Mcmillan EA, Zhao C, Mita M, Mita A, Chmielowski B, Postow MA, Ribas A, Mucida D, Tavazoie SF. Tavazoie MF, et al. Among authors: szarek m. Cell. 2018 Feb 8;172(4):825-840.e18. doi: 10.1016/j.cell.2017.12.026. Epub 2018 Jan 11. Cell. 2018. PMID: 29336888 Free PMC article.
Adherence-adjusted efficacy with intensive versus standard statin therapy in patients with acute myocardial infarction in the IDEAL study.
Holme I, Szarek M, Cater NB, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Larsen ML, Lindahl C, Pedersen TR; Incremental Decrease in End Points Through Aggressive Lipid Lowering Study Group. Holme I, et al. Among authors: szarek m. Eur J Cardiovasc Prev Rehabil. 2009 Jun;16(3):315-20. doi: 10.1097/HJR.0b013e32832130f5. Eur J Cardiovasc Prev Rehabil. 2009. PMID: 19322096 Clinical Trial.
Inflammation, statin therapy, and risk of stroke after an acute coronary syndrome in the MIRACL study.
Kinlay S, Schwartz GG, Olsson AG, Rifai N, Szarek M, Waters DD, Libby P, Ganz P; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Kinlay S, et al. Among authors: szarek m. Arterioscler Thromb Vasc Biol. 2008 Jan;28(1):142-7. doi: 10.1161/ATVBAHA.107.151787. Epub 2007 Nov 8. Arterioscler Thromb Vasc Biol. 2008. PMID: 17991875 Clinical Trial.
High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial.
Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, Larsen ML, Bendiksen FS, Lindahl C, Szarek M, Tsai J; Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group. Pedersen TR, et al. Among authors: szarek m. JAMA. 2005 Nov 16;294(19):2437-45. doi: 10.1001/jama.294.19.2437. JAMA. 2005. PMID: 16287954 Clinical Trial.
High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study.
Kinlay S, Schwartz GG, Olsson AG, Rifai N, Leslie SJ, Sasiela WJ, Szarek M, Libby P, Ganz P; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering Study Investigators. Kinlay S, et al. Among authors: szarek m. Circulation. 2003 Sep 30;108(13):1560-6. doi: 10.1161/01.CIR.0000091404.09558.AF. Epub 2003 Sep 15. Circulation. 2003. PMID: 12975259 Clinical Trial.
Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: Results from the MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering) trial.
Fraley AE, Schwartz GG, Olsson AG, Kinlay S, Szarek M, Rifai N, Libby P, Ganz P, Witztum JL, Tsimikas S; MIRACL Study Investigators. Fraley AE, et al. Among authors: szarek m. J Am Coll Cardiol. 2009 Jun 9;53(23):2186-96. doi: 10.1016/j.jacc.2009.02.041. J Am Coll Cardiol. 2009. PMID: 19497447 Free article. Clinical Trial.
130 results